• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OS Therapies Incorporated Common Stock (NY:OSTX)

1.320 -0.090 (-6.38%)
Official Closing Price Updated: 8:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 529,171
Open 1.420
Bid (Size) 1.330 (1,400)
Ask (Size) 1.400 (900)
Prev. Close 1.410
Today's Range 1.300 - 1.430
52wk Range 1.150 - 2.250
Shares Outstanding 5,847,955
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
October 06, 2026
72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company preparing to complete submissions for... 
Via Newsfile
News headline image
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
October 01, 2026
Experienced biotech leaders to focus on preparations for U.S., U.K., and European commercial launch of the Company's lead product candidate... 
Via Newsfile

Performance

52-Week Range 41.3% below 52-week high
1.320
1.1552W Low 2.2552W High
1 Week 18.7% below 1-week high
1.301W Low 1.621W High

OS Therapies Incorporated Common Stock (OSTX) traded between $1.15 and $2.25 over the past 52 weeks and last traded at $1.32, 41.3% below its 52-week high. Over the past week it ranged between $1.30 and $1.62.

Past 12 Months
-15.4%
-27.9%
-12.6%
-4.3%
-1.5%
-28.6%
1W -$0.24
1M -$0.51
3M -$0.19
6M -$0.06
YTD -$0.02
1Y -$0.53

OSTX was -28.6% over the past year, -4.3% over six months, -1.5% year to date, -15.4% in the last week.

12 Months vs Market
OSTX
-28.6%
DIA
+12.4%
SPY
+14.9%
QQQ
+17.5%
IWM
+11.1%

Over the past 12 months OSTX returned -28.6% versus DIA (Dow) +12.4%, SPY (S&P 500) +14.9%, QQQ (Nasdaq 100) +17.5% and IWM (Russell 2000) +11.1%.

Volume & Liquidity 0.91× 3-mo avg
Today 529,171 3-mo avg 578.4K
1W
490.0K
1M
819.6K
3M
578.4K
6M
697.5K
YTD
659.1K
1Y
597.2K

OSTX most recently traded 529,171 shares against a 3-month average daily volume of 578.4K.

More News

Read More
News headline image
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
September 24, 2026
Via Newsfile
News headline image
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
September 21, 2026
Via Newsfile
News headline image
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
September 17, 2026
Via Newsfile
News headline image
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
September 15, 2026
Via Newsfile
News headline image
OS Therapies Reports Strong Survival Data for Bone Cancer Treatment ↗
September 08, 2026
Via Benzinga
OS Animal Health Featured in Coverage of the Disruptive Growth & Life Sciences Conference
September 08, 2026
Via Investor Brand Network
News headline image
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
September 08, 2026
Via Newsfile
InvestorNewsBreaks – OS Therapies Inc. (NYSE American: OSTX) Heads to Moody Capital Conference Amid Major OST-HER2 Regulatory Push
September 03, 2026
Via Investor Brand Network
News headline image
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
September 02, 2026
Via Newsfile
News headline image
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
August 17, 2026
Via Newsfile
News headline image
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
August 13, 2026
Via Newsfile
News headline image
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
July 08, 2026
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Third Quarter 2026 Corporate Outlook
July 06, 2026
Via Newsfile
News headline image
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
July 02, 2026
Via Newsfile
News headline image
OS Therapies Provides U.S. Regulatory Update
June 30, 2026
Via Newsfile
News headline image
OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma
June 26, 2026
Via Newsfile
News headline image
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma
June 08, 2026
Via Newsfile
Topics Intellectual Property
News headline image
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
June 02, 2026
Via Newsfile
Topics Death Intellectual Property
News headline image
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
May 29, 2026
Via Newsfile
News headline image
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
May 26, 2026
Via Newsfile
News headline image
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update
May 18, 2026
Via Newsfile
Topics Regulatory Compliance
News headline image
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026
May 15, 2026
Via Newsfile
News headline image
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor
May 14, 2026
Via Newsfile

Frequently Asked Questions

Is OS Therapies Incorporated Common Stock publicly traded?
Yes, OS Therapies Incorporated Common Stock is publicly traded.
What exchange does OS Therapies Incorporated Common Stock trade on?
OS Therapies Incorporated Common Stock trades on the New York Stock Exchange
What is the ticker symbol for OS Therapies Incorporated Common Stock?
The ticker symbol for OS Therapies Incorporated Common Stock is OSTX on the New York Stock Exchange
What is the current price of OS Therapies Incorporated Common Stock?
The current price of OS Therapies Incorporated Common Stock is 1.320
When was OS Therapies Incorporated Common Stock last traded?
The last trade of OS Therapies Incorporated Common Stock was at 10/16/26 08:00 PM ET
What is the market capitalization of OS Therapies Incorporated Common Stock?
The market capitalization of OS Therapies Incorporated Common Stock is 7.72M
How many shares of OS Therapies Incorporated Common Stock are outstanding?
OS Therapies Incorporated Common Stock has 8M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap